GIST tumors linked to NF1 mutations, genetic testing needed

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A specific region of the small bowel, called the duodenal-jejunal flexure, shows a high frequency of gastrointestinal stromal tumors with mutations of the NF1 gene, according to researchers at UC San Diego Moores Cancer Center, Memorial Sloan Kettering Cancer Center and Fox Chase Cancer Center. The small bowel, where approximately 30 percent of all GISTs occur, is divided into three anatomically, histologically and functionally distinct segments: the duodenum, jejunum and ileum. Most small bowel GISTs are associated with KIT mutations. However, a subset of GISTs have mutations in other genes, such as NF1.“Where the duodenum transitions into the jejunum, we are finding an over-representation of NF1-mutated GIST,” said Jason Sicklick, a surgical oncologist at Moores Cancer Center.NF1 can be mutated both somatically (within tumor DNA) or in the germline (part of the hereditary condition called Neurofibromatosis type I). Patients with NF-1 are 34 times more likely to develop GIST than unaffected individuals.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

In this episode of The Cancer Letter Podcast, Fran Visco, president of the National Breast Cancer Coalition, and Jacquelyn Cobb, managing editor of The Cancer Letter, discuss the Metastatic Breast Cancer Act, bipartisan legislation that would eliminate the waiting periods for Social Security Disability Insurance and Medicare for eligible people with metastatic breast cancer. 
Congress settled the FY26 question in February, with NCI receiving $7.352 billion, an increase of $128 million over the prior year. After a year in which cancer center directors spent an extraordinary share of their leadership attention defending the research enterprise, that outcome deserves to be called what it was: a win.
Harold P. Freeman, a surgeon who started his career in Harlem, where, in addition to performing surgeries, he pioneered the system of patient navigation, and who studied health disparities and served as president of the American Cancer Society and chair of the President’s Cancer Panel, died on Aug. 11. He was 93.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login